search
Back to results

Point-of-care Ultrasound in Suspected Pulmonary Embolism

Primary Purpose

Pulmonary Embolism, Pulmonary Embolus/Emboli

Status
Active
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Point-of-care-ultrasound examination
Sponsored by
Odense University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Pulmonary Embolism focused on measuring Ultrasound, Diagnosis, Ultrasonography, Echocardiography

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Referred or Admitted to an emergency department
  • Clinical suspicion of PE raised by physician requiring further diagnostic imaging (Well's score 0-6 with elevated age-adjusted D-dimer or Wells score >6 regardless of D-dimer)

Exclusion Criteria:

  • Refusal of informed consent
  • Pregnancy
  • Permanent mental disability
  • Age <18 years
  • Diagnosis of PE within the last 6 months
  • Hemodynamic instability (systolic blood pressure <90 mmHg for at least two consecutive measurements)
  • Ultrasound of heart, lungs or deep veins performed prior to enrollment

Sites / Locations

  • Esbjerg Hospital
  • Kolding Hospital
  • Odense University Hospital
  • Slagelse hospital
  • Svendborg Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

PoCUS group

Control group

Arm Description

Patients allocated to the PoCUS investigation arm will receive an ultrasound investigation resulting in either confirmation or dismissal of pulmonary embolism suspicion or requiring CTPA or VQ

Patients allocated to the control group will continue with CTPA or VQ without PoCUS investigation

Outcomes

Primary Outcome Measures

Proportion of patients referred to CTPA or VQ after multiorgan PoCUS

Secondary Outcome Measures

Number of adverse events in the intervention and control group after inclusion, including readmission, serious bleeding or death
Number of hours until initiation of relevant treatment after clinical evaluation in the control and intervention group.
Proportion of included patients diagnosed with PE in the control and intervention group
Proportion of patients diagnosed with alternative diagnosis following clinical evaluation in the intervention and control group
Proportion of patients in the intervention and control group discharged to their own home following clinical evaluation
Proportion of patients in the reference and control group admitted to a cardiology department for telemetry monitoring (i.e. high risk PE) following clinical evaluation.
Proportion of patients in the reference and control group admitted to an intensive care unit following clinical evaluation
Proportion of patients in the reference and control group referred to supplementary CTPA or lung scintigraphy within 30 days after inclusion
Total costs related to diagnostic work up and hospital stay as assessed by HEAT 4.2
Number of subsequent cancer diagnosis in the intervention and control group within 3 months of inclusion

Full Information

First Posted
April 12, 2021
Last Updated
March 22, 2023
Sponsor
Odense University Hospital
Collaborators
University of Southern Denmark, Snedkermester Sophus Jacobsen and hustru Astrid Jacobsens Foundation, Odense Patient Data Explorative Network
search

1. Study Identification

Unique Protocol Identification Number
NCT04882579
Brief Title
Point-of-care Ultrasound in Suspected Pulmonary Embolism
Official Title
Point-of-care Ultrasound in the Diagnostic Work-up of Suspected Pulmonary Embolism - a Multicenter Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 15, 2021 (Actual)
Primary Completion Date
February 1, 2023 (Actual)
Study Completion Date
July 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Odense University Hospital
Collaborators
University of Southern Denmark, Snedkermester Sophus Jacobsen and hustru Astrid Jacobsens Foundation, Odense Patient Data Explorative Network

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Pulmonary embolism (PE) is a common cardiovascular condition with an estimated incidence of 0.60 to 1.12 per 1000 inhabitants in the United States of America, and the diagnosis is challenging as patients with PE present with a wide array of symptoms. Computed tomography pulmonary angriography (CTPA) and lung ventilation-perfusion scintigraphy (VQ) are considered the gold-standards in PE-diagnostics but may not always be feasible. CTPA is contraindicated by contrast allergy or renal failure and both modalities require involvement of multiple staff-members and transport of the patient. Lung scintigraphy cannot be performed in an emergency situation, with unstable patients and patients unable to comply to the examination. Ultrasound represent a possible tool in confirming or dismissing clinical PE suspicion. Ultrasound is non-invasive and can be performed bedside by the clinician, an approach known as point-of-care ultrasound (PoCUS), reducing both time, radiation-exposure and costs. The aim of this study is to investigate whether integrating cardiac, lung and deep venous ultrasound in the clinical evaluation of suspected PE reduces the need for referral to CTPA or lung scintigraphy, during emergency department work up, while maintaining safety standards.
Detailed Description
All ultrasound examinations will be performed by a physician certified in ultrasound by the Danish Society for Emergency Physicians in accordance with the Danish Health Agency. Based on ultrasonographic findings, PE suspicion is allocated to one of three categories: 1. Clinical suspicion of PE confirmed if ≥1 of the following ultrasound findings: Visible proximal deep venous thrombus ≥2 hypoechoic subpleural lung consolidations with a diameter of ≥0,5cm Visible right ventricular thrombus McConnell's sign if no known pulmonary hypertension, interstitial lung disease, COPD or pulmonary valve disease D-sign present in both systole and diastole if no known pulmonary hypertension, interstitial lung disease, COPD or pulmonary valve disease If PE is confirmed by ultrasound, the physician will apply the simplified pulmonary embolism severity index score (sPESI) and estimate risk of mortality within 30 days based on clinical signs and symptoms, cardiac troponin level and RV dysfunction. Patients with intermediate-high or high risk, requiring admission to a cardiology department will be referred for CTPA. Patients with low or intermediate-low risk, not requiring admission, will be discharged with anticoagulative treatment. A thorough presentation of the sPESI-score and early mortality risk assessment is available in the 2019 collaborative guidelines by the ERS and ESC on the diagnosis and management of PE. 2. Further diagnostic imaging (CTPA or V/Q) required if ≥1 of the following ultrasound findings: 1 hypoechoic subpleural lung consolidation with a diameter of ≥0,5cm Pleural effusion not explained by other cause Basal RVEDD/LVEDD >1.0 or an RV visibly larger than the LV TAPSE <17 mm No deep venous thrombus, no lung consolidation or effusion, no signs of RV strain or thrombus but strong clinical suspicion. McConnell's or D-sign in the presence of known pulmonary hypertension, interstitial lung disease, COPD or pulmonary valve disease If PE suspicion can be neither dismissed nor confirmed after ultrasound investigation, the patient will be referred to further investigation as usual with CTPA or lung scintigraphy. Subsequent plan will be in accordance with department guidelines. 3. Clinical suspicion of PE dismissed if ≥1 of the following ultrasound findings: No deep venous thrombus, no lung consolidation or effusion, no signs of RV strain or thrombus and a plausible differential diagnosis or low clinical suspicion Obvious differential diagnosis demonstrated on ultrasound (i.e., pneumonia, pneumothorax, interstitial syndrome, left sided heart failure) If PE suspicion is dismissed by ultrasound investigation, the patient will be either discharged or subject to further investigations in accordance with department guidelines if indicated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Embolism, Pulmonary Embolus/Emboli
Keywords
Ultrasound, Diagnosis, Ultrasonography, Echocardiography

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
150 patients with suspected pulmonary embolism, requiring CTPA or VQ to finally confirm or dismiss the diagnosis will be enrolled and randomized 1:1 to receive a multiorgan ultrasound investigation or continue to CTPA or VQ as planned.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PoCUS group
Arm Type
Experimental
Arm Description
Patients allocated to the PoCUS investigation arm will receive an ultrasound investigation resulting in either confirmation or dismissal of pulmonary embolism suspicion or requiring CTPA or VQ
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Patients allocated to the control group will continue with CTPA or VQ without PoCUS investigation
Intervention Type
Diagnostic Test
Intervention Name(s)
Point-of-care-ultrasound examination
Intervention Description
The intervention consists of three ultrasound modalities: Cardiac ultrasound assessing signs of right ventricular strain or other obvious pathology. Deep venous ultrasound assessing presence of a deep venous thrombus Lung ultrasound assessing presence of pulmonary infarctions, pleural effusion, pneumothorax or interstitial syndrome.
Primary Outcome Measure Information:
Title
Proportion of patients referred to CTPA or VQ after multiorgan PoCUS
Time Frame
Up to 24 hours
Secondary Outcome Measure Information:
Title
Number of adverse events in the intervention and control group after inclusion, including readmission, serious bleeding or death
Time Frame
3 months
Title
Number of hours until initiation of relevant treatment after clinical evaluation in the control and intervention group.
Time Frame
Up to 24 hours
Title
Proportion of included patients diagnosed with PE in the control and intervention group
Time Frame
Up to 24 hours
Title
Proportion of patients diagnosed with alternative diagnosis following clinical evaluation in the intervention and control group
Time Frame
Up to 24 hours
Title
Proportion of patients in the intervention and control group discharged to their own home following clinical evaluation
Time Frame
Up to 24 hours
Title
Proportion of patients in the reference and control group admitted to a cardiology department for telemetry monitoring (i.e. high risk PE) following clinical evaluation.
Time Frame
Up to 24 hours
Title
Proportion of patients in the reference and control group admitted to an intensive care unit following clinical evaluation
Time Frame
Up to 24 hours
Title
Proportion of patients in the reference and control group referred to supplementary CTPA or lung scintigraphy within 30 days after inclusion
Time Frame
30 days
Title
Total costs related to diagnostic work up and hospital stay as assessed by HEAT 4.2
Time Frame
Up to 1 year
Title
Number of subsequent cancer diagnosis in the intervention and control group within 3 months of inclusion
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Referred or Admitted to an emergency department Clinical suspicion of PE raised by physician requiring further diagnostic imaging (Well's score 0-6 with elevated age-adjusted D-dimer or Wells score >6 regardless of D-dimer) Exclusion Criteria: Refusal of informed consent Pregnancy Permanent mental disability Age <18 years Diagnosis of PE within the last 6 months Hemodynamic instability (systolic blood pressure <90 mmHg for at least two consecutive measurements) Ultrasound of heart, lungs or deep veins performed prior to enrollment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Casper Falster, MD
Organizational Affiliation
Odense University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christian B Laursen, Prof. MD
Organizational Affiliation
Odense University Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Esbjerg Hospital
City
Esbjerg
ZIP/Postal Code
6700
Country
Denmark
Facility Name
Kolding Hospital
City
Kolding
ZIP/Postal Code
6000
Country
Denmark
Facility Name
Odense University Hospital
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Facility Name
Slagelse hospital
City
Slagelse
ZIP/Postal Code
4200
Country
Denmark
Facility Name
Svendborg Hospital
City
Svendborg
ZIP/Postal Code
5700
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Point-of-care Ultrasound in Suspected Pulmonary Embolism

We'll reach out to this number within 24 hrs